Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

SIMPLE SUMMARY: Tamoxifen is an important adjuvant endocrine therapy in estrogen receptor (ER)-positive breast cancer patients. It is mainly catalyzed by the enzyme CYP2D6 into the most active metabolite endoxifen. Genetic variation in the CYP2D6 gene influences endoxifen formation and thereby poten...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Mulder, Tessa A. M., de With, Mirjam, del Re, Marzia, Danesi, Romano, Mathijssen, Ron H. J., van Schaik, Ron H. N.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7917604/
https://ncbi.nlm.nih.gov/pubmed/33673305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040771
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados